Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.36 USD
-0.03 (-7.13%)
Updated Jul 25, 2024 12:08 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Panbela Therapeutics Inc. [PBLA]
Reports for Purchase
Showing records 1 - 20 ( 76 total )
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 ASPIRE Secures Third Green Light to Advance; Interim Analysis Expected by 1Q25
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Cash and Listing Risk Significantly Detract From Underlying Fundamentals; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Awaiting Data Readouts to Assure Path Forward; Target Adjusted Downward to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Valuation Does Not Reflect Near-Term Potential Broad Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology and Medical Device Conference Note
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Optimism for Phase 3 SBP-101 Trial Upon NALIPIFOX 1st-Line mPDAC Approval
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ASPIRE 50% Enrolled, Recent DFMO Data Published, Cash Position Fortified
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
FDA Approves US WorldMeds'' Eflornithine NDA in Pediatric Neuroblastoma
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
FDA Approval of Eflornithine in Neuroblastoma Validates Panbela''s Pipeline and Boosts Cash Reserves
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Published Abstract Shows SBP-101 DFMO In-Vitro Inhibition of MM Cells
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ASPIRE Passes Second DSMB Safety Review, Trial to Continue As Planned
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 ASPIRE Gets Second Green Light; Interim Analysis Expected in Early 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q23: Valuation Does Not Reflect Near Term Potential Broad Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Clinical Pipeline Nears 2024 Data Readouts; Financial Overhang Looms
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Issued New E.U. Patent for Novel SBP-101 Production Process
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J